RxDoctor Payments Data

Richard Sutton, DO

Gastroenterology · Overland Park, KSNPI 1760879639

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 123 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by AbbVie at 58.7% of the total. 2025 is the largest year on record at $596, more than ten times the $31 reported in 2019.

$1,741in general payments, 2019–2025

Across 123 payments — averaging $14.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Bristol Myers Squibb$165
  • Pfizer$127
  • Takeda Pharmaceuticals U.S.A., Inc.$71
  • Boston Scientific$49
  • Celltrion USA Inc.$39
  • plus $268 from 11 others

What the payments were for

  • Food & beverage$1,741100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,741 in reported general payments places this provider in the 55th percentile of 98 gastroenterology providers in Kansas.

See all gastroenterology providers in Kansas

Medicare billing

Part B allowed, 2024
$178,321
Medicare patients
429
Services billed
3,753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$293,918
LinzessLinaclotide31$29,635
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates196$13,047
Omeprazole178$4,033
Mesalamine13$2,753
Pantoprazole Sodium136$1,827
Colestipol Hcl14$944
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl55$724
Mesalamine ErMesalamine12$678
Esomeprazole Magnesium11$577
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl20$302
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine12$182
Famotidine14$57
Ondansetron OdtOndansetron11$11

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$28$293,91811 claims
AbbVieLinzess$1,022$29,63531 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 98 gastroenterology providers in Kansas.

Other gastroenterology in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →